Gilead Cuts Full-Year Guidance, Expects Loss on Acquired R&D Charges
Gilead Sciences reported continued growth in its HIV drug franchise but trimmed its full-year revenue guidance and disclosed it expects an operating loss for fiscal 2026 due to elevated acquired R&D expenses. The stock declined after the mixed outlook and ongoing integration costs from recent acquisitions.
1. HIV Franchise Continues Growth
Gilead’s HIV therapy business delivered year-over-year revenue gains in the latest quarter, as demand for its core antiretroviral treatments remained strong across major markets. This segment’s performance provided a rare bright spot amid broader pipeline and expense pressures.
2. Full-Year Guidance and Loss Outlook
The company reduced its full-year revenue guidance following an uptick in acquired R&D expenses tied to recent deal activity. Gilead now forecasts an operating loss for fiscal 2026, driven by higher amortization and integration charges from those acquisitions.
3. Market Reaction and Integration Costs
Shares fell after the earnings release and revised outlook, reflecting investor concerns over escalating integration costs and elevated R&D spend. Market participants are watching closely for updates on pipeline milestones and cost synergies from the company’s recent transactions.